Switch View
© BusinessWire
04.11.2025
ISIN: US30063P1057
Exact Sciences Corp
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in November Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jefferies London Healthcare Conference, London
Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US98978V1035
Zoetis Inc
ZTS
LISTED
NYSE
Zoetis Announces Third Quarter 2025 Results
News Preview
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.
The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 20...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface ant...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.11.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
News Preview
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“I am proud of Pfizer’s leadership as the first in our industry to reach an agreemen...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
04.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerl...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US09075A1088
Bioventus Inc
BVS
LISTED
NASDAQ
Bioventus Reports Third Quarter Financial Results
News Preview
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
News Preview
WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no FDA-approved therapies, today announced that it will report it...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Participate in November Investor Conferences
News Preview
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier, Inc. Reports Fiscal-Year 2026 First-Quarter Financial Results
News Preview
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2026 first quarter ended September 30, 2025.
Fiscal-year 2026 first quarter total net revenue of $240.0 million decreased 3% from the prior-year period. Net income from continuing operations of $15.3 mill...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US45685K1025
InfuSystem Holdings Inc
INFU
LISTED
XASE
InfuSystem Reports Third Quarter 2025 Financial Results
News Preview
InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2025.
2025 Third Quarter Overview:
Net rev...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US8688731004
Surmodics Inc
SRDX
LISTED
NASDAQ
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
News Preview
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US67576A1007
Ocular Therapeutix Inc
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
04.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
Prelude Therapeutics Announces Strategic Business Update
News Preview
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US64131A1051
Neuronetics Inc
STIM
LISTED
NASDAQ
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
News Preview
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
News Preview
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end
21.1 month median OS and 7.0 month median PFS reported from single-arm...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US9418481035
Waters Corp
WAT
LISTED
NYSE
Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
News Preview
Highlights
Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency
Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% g...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US9418481035
Waters Corp
WAT
LISTED
NYSE
Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
News Preview
Highlights
Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency
Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% g...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US83601L1026
Sotera Health Co
SHC
LISTED
NASDAQ
Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
News Preview
Sotera Health Q3 2025 Earnings Release...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US76243J1051
Rhythm Pharmaceuticals Inc
RYTM
LISTED
NASDAQ
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
News Preview
-- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity --...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US07373V1052
Beam Therapeutics Inc
BEAM
LISTED
NASDAQ
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
News Preview
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US5015751044
Kymera Therapeutics Inc
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
News Preview
Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US03152W1099
Amicus Therapeutics Inc
FOLD
LISTED
NASDAQ
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
News Preview
Q3 2025 Total Revenue of $169M, up 17% at CER...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US95075A1079
Werewolf Therapeutics Inc
HOWL
LISTED
NASDAQ
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US5588681057
Madrigal Pharmaceuticals Inc
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
News Preview
CONSHOHOCKEN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2025 financial results and provides corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: CH0329023102
AC Immune SA
ACIU
LISTED
NASDAQ
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US45779A8466
InspireMD, Inc.
NSPR
LISTED
NASDAQ
InspireMD Reports Third Quarter 2025 Financial Results
News Preview
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: CA05156V1022
Aurinia Pharmaceuticals Inc
AUPH
LISTED
NASDAQ
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
News Preview
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress.
Financial Results
Total Revenue: For the three and nine months ended September 30, 2025, total revenue was $73.5 million and $205.9 million, up 8% and 17%, resp...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US8064071025
Henry Schein Inc
HSIC
LISTED
NASDAQ
Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance
News Preview
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 27, 2025.
“We are pleased with our financial results for the third quarter, with sales growth accelerating in each of our reportable segme...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Montega AG: Medios AG | Rating: Kaufen
News Preview
Original-Research: Medios AG - von Montega AG
04.11.2025 / 11:41 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss......
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US50127T1097
Kura Oncology Inc
KURA
LISTED
NASDAQ
Kura Oncology Reports Third Quarter 2025 Financial Results
News Preview
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: CA72706K1012
Planet 13 Holdings Inc.
PLTH
LISTED
CSE
Planet 13 Announces Release Date of Third Quarter 2025 Financial Results
News Preview
LAS VEGAS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, announced today that it plans to release its financial results for the third quarter ended September 30th, 2025, on November 12th, 2025, aftermarket....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US2210061097
CorVel Corp
CRVL
LISTED
NASDAQ
CorVel Announces Revenues and Earnings
News Preview
FORT WORTH, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended September 30, 2025. Revenues for the quarter were $240 million, an increase from $224 million in the September quarter of 2024. Earnings per share for the quarter were $0.54, compared to $0.45 in the same quarter of t...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US7504911022
RadNet Inc
RDNT
LISTED
NASDAQ
RadNet Announces the Agenda for its November 11, 2025 Investor Day
News Preview
RadNet Announces the Agenda for its November 11, 2025 Investor Day...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: JP3431300007
Nxera Pharma Co Ltd
45650
LISTED
XJPX
Nxera Pharma to Host R&D Day 2025
News Preview
Tokyo, Japan and Cambridge, UK, 4 November 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces that it will hold an R&D Day on 18 November 2025 at 17:00 JST....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an a...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an a...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2025
ISIN: US9174881089
Utah Medical Products Inc
UTMD
LISTED
NASDAQ
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
News Preview
SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors. Mr. Timken, who served as UTMD's outside legal counsel for over twenty years prior to his retirement in 2025, graduated with a J.D. degree from the Un...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
ISIN: CA24463V1013
Defence Therapeutics Inc.
DTC
LISTED
CSE
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
News Preview
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from it...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2025
ISIN: CA00143Y1034
AI-ML Innovations Inc.
AIML
LISTED
CSE
AIML Subsidiary NeuralCloud Solutions Engages Lonacas Consultants to Lead Regulatory Submission for CardioYield(TM) in Jamaica
News Preview
Collaboration Advances Local Regulatory Pathway for AI-Enabled ECG Diagnostics to Address the Growing Cardiovascular Disease Burden in Jamaica TORONTO, ON / ACCESS Newswire / November 4, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that its wholly owned subsidia...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
News Preview
COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: CH0432492467
Alcon AG
ALC
LISTED
NYSE
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
News Preview
Alcon (SIX/NYSE: ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (SEC). Alcon plans to initiate outreach to STAAR stockholders and the presentation highlights key considera...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: KR7145020004
Hugel, Inc.
145020
LISTED
KOE
Hugel posts KRW105.9 billion in Q3 net sales on continued global growth
News Preview
- Operating profit and net income reached KRW47.4 billion and KRW38 billion, respectively; the company marked two consecutive quarters surpassing KRW100 billion in net sales
- Combined toxin and filler sales in the global Big Four markets – the US, China, Europe, and Brazil – accounted for 45% o...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
News Preview
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast A/S - Full-Year Financial Results 2024/25
News Preview
2024/25Full year financial results...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: CH0011432447
Basilea Pharmaceutica AG Allschwil
BSLN
LISTED
SIX
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: US73245B1070
SBC Medical Group Holdings, Inc.
SBC
LISTED
NASDAQ
The Chelsea Clinic Expands into New Flagship at Ngee Ann City
News Preview
About The Chelsea ClinicFounded in 1999, The Chelsea Clinic is part of a network of medical aesthetic and wellness clinics in Singapore and a member of the SBC Medical Group, a medical and aesthetic services provider headquartered in Irvine, California, and listed on Nasdaq (Nasdaq: SBC). With more than two decades of experience, The Chelsea Clini......
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: KYG0519B1023
Ascentage Pharma Group International
6855
LISTED
HKSE
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
News Preview
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announce...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: KYG0519B1023
Ascentage Pharma Group International
6855
LISTED
HKSE
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
News Preview
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announce...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
News Preview
SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025. DexCom is a medical device company primarily focused on the des...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US88033G4073
Tenet Healthcare Corp
THC
LISTED
NYSE
Tenet Announces Upsizing and Pricing of Its $2.25 Billion Private Offerings of Senior Secured Notes and Senior Notes
News Preview
Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the “first lien notes”), and $0....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US0029421007
Aardvark Therapeutics Inc
AARD
LISTED
NASDAQ
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting o...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US42222N1037
HealthStream Inc
HSTM
LISTED
NASDAQ
HealthStream Announces Third Quarter 2025 Results
News Preview
HealthStream, Inc. (the "Company") (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today results for the third quarter ended September 30, 2025.
Third Quarter 2025
Revenues of $76.5 million in the third quarter of 2025, up 4.6% from $73.1 million in the third quarter of 2024, setting a new C...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US98943L1070
Zentalis Pharmaceuticals Inc
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on November 3, 2025, the Compensation Committee of Zentalis’ Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US1420381089
Caribou Biosciences Inc
CRBU
LISTED
NASDAQ
Caribou Biosciences to Participate in Upcoming Investor Conferences
News Preview
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US92337F1075
Veracyte Inc
VCYT
LISTED
NASDAQ
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool’s ability to help define the future of thyroid nodule evaluation. Using the company’s innovative whole-transcriptome-derived research-use-only...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US98978V1035
Zoetis Inc
ZTS
LISTED
NYSE
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
News Preview
Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed K...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
